Abstract

 CADTH recommends that Rylaze be reimbursed by public drug plans as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 year or older who have developed hypersensitivity to Escherichia coli–derived asparaginase if certain conditions are met.
 Rylaze (crisantaspase recombinant) should only be covered to treat patients who have ALL or LBL with documented hypersensitivity to (or silent inactivation of) an coli–derived asparaginase.
 Rylaze should only be reimbursed as part of a multicomponent treatment regimen to replace pegylated coli–derived asparaginases (pegaspargase), following hypersensitivity or silent inactivation of the E. coli–derived asparaginase. Rylaze should be prescribed by clinicians with expertise in the management of ALL or LBL, and the cost of Rylaze should be reduced.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
